Pediatric Therapy Articles & Analysis: Older
2 news found
In 2019, NeuroSigma’s Monarch eTNS System became the first-ever non-pharmaceutical treatment to receive FDA clearance as a treatment for pediatric ADHD. To deliver therapy with the Monarch, patients place an adhesive electric patch on their forehead. ...
Will drive commercial strategy and execution of Tadekinig alfa, currently in Phase 3 Joins AB2 Bio from Novartis and has extensive commercial and strategic experience AB2 Bio Ltd., a Phase 3 clinical-stage biotech company developing innovative therapies for the treatment of severe systemic autoinflammatory diseases, today announced the appointment of Djordje Filipovic, PhD, ...